| Withdrawn | Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs NCT04985357 | Travera Inc | — |
| Completed | Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx) NCT05461430 | Travera Inc | — |
| Active Not Recruiting | Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Express NCT04802876 | SOLTI Breast Cancer Research Group | Phase 2 |
| Completed | Postoperative Pain, Why Still in Hospital and DAOH Following TORS for SCCUP & OSAS NCT04189107 | Rigshospitalet, Denmark | Phase 3 |
| Recruiting | Cancer Genetic Testing in Ethnic Populations NCT04475640 | Mayo Clinic | N/A |
| Active Not Recruiting | Pembrolizumab in Patients With Poor-Prognosis Carcinoma of Unknown Primary Site (CUP) NCT03391973 | AHS Cancer Control Alberta | Phase 2 |
| Recruiting | Blood Tests and Questionnaires in Studying Adherence to Preventative Swallowing Exercises in Participants With NCT03010150 | M.D. Anderson Cancer Center | — |
| Active Not Recruiting | Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic NCT02721732 | M.D. Anderson Cancer Center | Phase 2 |
| Unknown | Phase 2 Study of Gemcitabine and Docetaxel Combination Chemotherapy in Patients With Carcinoma of Unknown Prim NCT02590055 | Samsung Medical Center | Phase 2 |
| Recruiting | Genomic Investigation of Unusual Responders NCT03740503 | University Health Network, Toronto | — |
| Active Not Recruiting | Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be NCT01366144 | National Cancer Institute (NCI) | Phase 1 |
| Unknown | Elective Mucosal Irradiation in Head-and-Neck Cancer of Unknown Primary NCT02764216 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Phase 2 |
| Completed | Belinostat, Carboplatin and Paclitaxel (BelCaP) Compared to Carboplatin and Paclitaxel in Patients With Cancer NCT00873119 | Valerio Therapeutics | Phase 2 |
| Completed | Gemcitabine in Treating Patients With Metastatic Cancer of Unknown Primary NCT00357630 | Eastern Cooperative Oncology Group | Phase 2 |
| Completed | PET Scans and CT Scans in Patients With Locally Advanced Head and Neck Cancer Undergoing Chemotherapy and Radi NCT00388024 | Wake Forest University Health Sciences | — |
| Terminated | Topotecan in Treating Young Patients With Neoplastic Meningitis Due to Leukemia, Lymphoma, or Solid Tumors NCT00112619 | Pediatric Brain Tumor Consortium | Phase 1 |
| Withdrawn | Gemcitabine, Docetaxel, and Capecitabine in Treating Patients With Cancer of Unknown Primary Origin NCT00119314 | University of Medicine and Dentistry of New Jersey | Phase 2 |
| Completed | Gemcitabine and Irinotecan in Treating Patients With Cancer of Unknown Primary NCT00066781 | Alliance for Clinical Trials in Oncology | Phase 2 |
| Completed | Radiation Therapy in Treating Patients With Metastases to the Lymph Nodes in the Neck From an Unknown Primary NCT00047125 | European Organisation for Research and Treatment of Cancer - EORTC | Phase 3 |
| Terminated | Combination of Carboplatin, Gemcitabine, and Capecitabine in Patients With Carcinoma of Unknown Primary Site NCT00148135 | University of Michigan Rogel Cancer Center | Phase 2 |
| Completed | SU5416 in Treating Patients With Advanced or Recurrent Cancer of the Head and Neck NCT00006361 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors NCT00014456 | Dartmouth-Hitchcock Medical Center | Phase 1 |
| Completed | Irinotecan in Treating Patients With Advanced Neuroendocrine Tumors NCT00004922 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Unknown | Combination Chemotherapy in Treating Patients With Metastatic Cancer of an Unknown Site of Origin NCT00022178 | The Christie NHS Foundation Trust | Phase 3 |
| Completed | Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Cancer NCT00003943 | Fox Chase Cancer Center | Phase 2 |
| Completed | Irinotecan Followed By Fluorouracil and Leucovorin in Treating Patients With Stage III or Stage IV Colorectal NCT00004005 | St. Jude Children's Research Hospital | Phase 2 |
| Unknown | Chemotherapy in Treating Patients With Cancer of Unknown Primary Origin NCT00003558 | Academisch Ziekenhuis Maastricht | Phase 3 |
| Completed | High-dose ICE With Amifostine NCT00003657 | Dana-Farber Cancer Institute | Phase 2 |
| Completed | Radiation Therapy and Chemotherapy in Treating Patients With Head and Neck Cancer NCT00002507 | Yale University | Phase 3 |
| Completed | Radiation Therapy, Combination Chemotherapy, and Amifostine in Treating Patients With Head and Neck Cancer NCT00003582 | University of Miami | Phase 1 / Phase 2 |